Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Novartis
Novartis
Hoffmann-La Roche
Hoffmann-La Roche
BeOne Medicines
M.D. Anderson Cancer Center
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
M.D. Anderson Cancer Center
Ottawa Hospital Research Institute
Tesaro, Inc.
Gilead Sciences
University of Kentucky
Eli Lilly and Company
Incyte Corporation
Suzhou Junjing BioSciences Co., Ltd.
Sutro Biopharma, Inc.
STCube, Inc.
Mural Oncology, Inc
Bio-Thera Solutions
Fox Chase Cancer Center
invoX Pharma Limited
University of Maryland, Baltimore
SOLTI Breast Cancer Research Group
Imugene Limited
Bristol-Myers Squibb
National Cancer Institute (NCI)
Amgen
Bristol-Myers Squibb
Peking University
Ohio State University Comprehensive Cancer Center
Handok Inc.
Tufts Medical Center
National Cancer Institute (NCI)
Astellas Pharma Inc
AbbVie
Pfizer
NantCell, Inc.
Taiho Oncology, Inc.
University of Miami
EQRx International, Inc.
Kyowa Kirin Co., Ltd.
Fox Chase Cancer Center
M.D. Anderson Cancer Center
1200 Pharma, LLC
Puma Biotechnology, Inc.
EMD Serono
University of Nebraska
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hoosier Cancer Research Network
Sumitomo Pharma America, Inc.
University of Texas Southwestern Medical Center